Adaptimmune Therapeutics Q1 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $5.678M Miss $10.733M Estimate
Adaptimmune Therapeutics Q1 2024 GAAP EPS $(0.03) Beats $(0.09) Estimate, Sales $5.678M Miss $10.733M Estimate
Adaptimmune Therapeutics 2024年第一季度GAAP每股收益美元（0.03美元）超过预期（0.09美元），销售额为567.8万美元，低于1073.3万美元的预期
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.09) by 66.67 percent. The company reported quarterly sales of $5.678 million which missed the analyst consensus estimate of $10.733 million by 47.10 percent. This is a 88.07 percent decrease over sales of $47.601 million the same period last year.
Adaptimmune Therapeutics（纳斯达克股票代码：ADAP）公布的季度亏损为每股0.03美元，比分析师普遍预期的0.09美元（0.09美元）高出66.67％。该公司公布的季度销售额为567.8万美元，比分析师普遍预期的1073.3万美元低47.10％。这比去年同期的4,7601万美元的销售额下降了88.07％。